Stryker (SYK) Stock
Global medical device maker selling surgical tools and implants. Here's the price, business snapshot, and what's worth knowing about Stryker in November 2026.
Stryker Corporation (SYK) is a global medical‑technology company best known for orthopaedics, surgical equipment, neurotechnology and patient-handling systems. Investors should know it sells high-margin implants, powered surgical tools and capital equipment to hospitals and clinics, giving it exposure to both recurring consumable sales and larger, cyclical procedure volumes. Growth drivers include an ageing population, innovation in implants and minimally invasive procedures, geographic expansion and selective acquisitions. Key considerations are sensitivity to elective-surgery cycles, hospital capital spending and regulatory approvals; reimbursement policies and competition from other device makers can also affect results. Stryker has a track record of reinvesting in R&D, pursuing M&A and returning cash to shareholders, but margins and growth rates can vary over time. This is general, educational information only — not personal investment advice. Values can rise and fall and past performance is not a reliable guide. Suitability depends on your circumstances; consider seeking regulated financial advice before investing.
Why It’s Moving
Stryker Shares Slide as Q3 Miss and 2026 Outlook Cut Signal Execution Risks
- Adjusted EPS of $3.52 missed consensus estimates of $3.56, while organic sales growth of 7.7% failed to offset broader operational headwinds.
- Management lowered the 2026 outlook due to softer hip and knee procedure volumes and unresolved manufacturing issues in peripheral vascular products that previously wiped out over $10 billion in market capitalization.
- Despite strength in MedSurg and robotics investments, execution risks tied to capital equipment sales and supply disruptions continue to weigh on investor sentiment.
Stryker Shares Slide as Q3 Miss and 2026 Outlook Cut Signal Execution Risks
- Adjusted EPS of $3.52 missed consensus estimates of $3.56, while organic sales growth of 7.7% failed to offset broader operational headwinds.
- Management lowered the 2026 outlook due to softer hip and knee procedure volumes and unresolved manufacturing issues in peripheral vascular products that previously wiped out over $10 billion in market capitalization.
- Despite strength in MedSurg and robotics investments, execution risks tied to capital equipment sales and supply disruptions continue to weigh on investor sentiment.
Sixth Month Growth Performance
When is the next earnings date for STRYKER CORP (SYK)?
Stryker Corporation has not yet announced a confirmed date for its next earnings report. Based on the company's historical reporting pattern, which typically follows a quarterly cadence of approximately three months after the previous release, the next report is expected in late January 2027. This upcoming disclosure will cover financial results for the fourth quarter and full fiscal year ending December 31, 2026.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Stryker's stock, believing it has significant potential for growth.
Financial Health
Stryker Corp is performing well with strong profits and cash flow, indicating solid financial stability.
Dividend
Stryker Corp's dividend yield of 1.22% is below average, indicating modest returns for dividend-seeking investors. If you invested $1000 you would be paid $12.20 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Elective Surgery Exposure
Stryker benefits from demand for joint replacements and minimally invasive procedures, though revenues can move with surgical volumes and economic cycles.
Innovation and M&A
Regular new-product launches and selective acquisitions can extend market share, but integration and regulatory approval carry execution risk.
Global Footprint
Diversified geographic presence helps growth and resilience, though it brings exposure to local reimbursement policies and currency fluctuations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
